If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Forteo ® (teriparatide injection)
20-mcg daily dose in a 2.4-mL prefilled delivery device
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
FORTEO® (teriparatide [rDNA origin] injection): Fracture Risk Reduction
Forteo reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.
Teriparatide reduced the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis.1
Teriparatide was effective in reducing the risk for vertebral fractures regardless of age, baseline rate of bone turnover, or baseline BMD.1
Compared to placebo, teriparatide treatment significantly reduced the risk of incident vertebral fractures and nonvertebral fractures (Table 1).1
Table 1. Effect of Teriparatide on Risk of Vertebral and Nonvertebral Fractures in Postmenopausal Women With Osteoporosis1
|
|
Placebo n=544 % |
Teriparatide n=541 % |
Absolute Risk Reduction % |
Relative Risk Reduction % (95% CI) |
|
Incident vertebral fracture (≥1) |
14.3 |
5.0a |
9.3 |
65 (45-78) |
|
Incident nonvertebral fracture (≥1) |
5.5 |
2.6b |
2.9 |
53 (12-75) |
a p<.001 compared to placebo.
Enclosed Prescribing Information
FORTEO® (teriparatide [rDNA origin] injection), Lilly
1. Forteo [package insert]. Indianapolis IN: Eli Lilly and Company; 2019.
Glossary
BMD = bone mineral density
Date of Last Review: February 18, 2020